Mohammad Aquib Siddiqui, Abhishek Pathak, Kakarla Ramakrishna, Sairam Krishnamurthy
{"title":"雷诺嗪通过调节脑源性神经营养因子和脑线粒体tu翻译延伸因子(TUFM)对大脑中动脉闭塞/再灌注缺血性损伤的神经保护作用。","authors":"Mohammad Aquib Siddiqui, Abhishek Pathak, Kakarla Ramakrishna, Sairam Krishnamurthy","doi":"10.1007/s11011-025-01708-5","DOIUrl":null,"url":null,"abstract":"<p><p>The present study investigates the therapeutic potential of Ranolazine in cerebral ischemic stroke, focusing on its neuroprotective properties in a middle cerebral artery occlusion/reperfusion (MCAO/R) induced ischemic brain injury in a rat model. Ranolazine demonstrated neuroprotective effects by reducing infarct size and brain edema, improving cerebral blood flow, and preserving blood-brain barrier integrity, leading to improved neurological function. Mechanistically, ranolazine decreased HIF-1α and GFAP expression while enhancing BDNF levels. Ranolazine increased mitochondrial complex enzyme activities (I, II, IV, and V) and enhanced the expression of the mitochondrial Tu translation elongation factor (TUFM), NRF1, and PGC-1α levels, indicating improved mitochondrial biogenesis and decreased mitochondrial oxidative stress markers such as 4-HNE and increased catalase and SOD. Further, ranolazine treatment reduced the levels of pro-inflammatory cytokines TNF-α and IL-6 while increasing the anti-inflammatory cytokine IL-10, suggesting its anti-inflammatory potential in mitigating the stroke-associated neuroinflammation. Moreover, ranolazine suppressed apoptosis by reducing the levels of apoptotic mediators such as cytochrome c, caspase-9, and caspase-3, and flow cytometry analysis revealed a significant decline in neuronal apoptosis, which further underscores its neuroprotective efficacy. Therefore, the novelty of this research lies in demonstrating that ranolazine exerts neuroprotective effects against ischemic brain injury by simultaneously modulating apoptotic pathways, restoring vital neurological factors (BDNF, TUFM, NRF-1, PGC-1α), improving mitochondrial function, reducing oxidative stress, and attenuating neuroinflammation, offering a novel multi-targeted therapeutic approach, meriting further clinical studies.</p>","PeriodicalId":18685,"journal":{"name":"Metabolic brain disease","volume":"40 7","pages":"285"},"PeriodicalIF":3.5000,"publicationDate":"2025-10-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Ranolazine neuroprotection against middle cerebral artery occlusion/reperfusion ischemic injury via modulation of brain-derived neurotrophic factor and brain mitochondrial tu translation elongation factor (TUFM).\",\"authors\":\"Mohammad Aquib Siddiqui, Abhishek Pathak, Kakarla Ramakrishna, Sairam Krishnamurthy\",\"doi\":\"10.1007/s11011-025-01708-5\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>The present study investigates the therapeutic potential of Ranolazine in cerebral ischemic stroke, focusing on its neuroprotective properties in a middle cerebral artery occlusion/reperfusion (MCAO/R) induced ischemic brain injury in a rat model. Ranolazine demonstrated neuroprotective effects by reducing infarct size and brain edema, improving cerebral blood flow, and preserving blood-brain barrier integrity, leading to improved neurological function. Mechanistically, ranolazine decreased HIF-1α and GFAP expression while enhancing BDNF levels. Ranolazine increased mitochondrial complex enzyme activities (I, II, IV, and V) and enhanced the expression of the mitochondrial Tu translation elongation factor (TUFM), NRF1, and PGC-1α levels, indicating improved mitochondrial biogenesis and decreased mitochondrial oxidative stress markers such as 4-HNE and increased catalase and SOD. Further, ranolazine treatment reduced the levels of pro-inflammatory cytokines TNF-α and IL-6 while increasing the anti-inflammatory cytokine IL-10, suggesting its anti-inflammatory potential in mitigating the stroke-associated neuroinflammation. Moreover, ranolazine suppressed apoptosis by reducing the levels of apoptotic mediators such as cytochrome c, caspase-9, and caspase-3, and flow cytometry analysis revealed a significant decline in neuronal apoptosis, which further underscores its neuroprotective efficacy. Therefore, the novelty of this research lies in demonstrating that ranolazine exerts neuroprotective effects against ischemic brain injury by simultaneously modulating apoptotic pathways, restoring vital neurological factors (BDNF, TUFM, NRF-1, PGC-1α), improving mitochondrial function, reducing oxidative stress, and attenuating neuroinflammation, offering a novel multi-targeted therapeutic approach, meriting further clinical studies.</p>\",\"PeriodicalId\":18685,\"journal\":{\"name\":\"Metabolic brain disease\",\"volume\":\"40 7\",\"pages\":\"285\"},\"PeriodicalIF\":3.5000,\"publicationDate\":\"2025-10-10\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Metabolic brain disease\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1007/s11011-025-01708-5\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"ENDOCRINOLOGY & METABOLISM\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Metabolic brain disease","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s11011-025-01708-5","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}
Ranolazine neuroprotection against middle cerebral artery occlusion/reperfusion ischemic injury via modulation of brain-derived neurotrophic factor and brain mitochondrial tu translation elongation factor (TUFM).
The present study investigates the therapeutic potential of Ranolazine in cerebral ischemic stroke, focusing on its neuroprotective properties in a middle cerebral artery occlusion/reperfusion (MCAO/R) induced ischemic brain injury in a rat model. Ranolazine demonstrated neuroprotective effects by reducing infarct size and brain edema, improving cerebral blood flow, and preserving blood-brain barrier integrity, leading to improved neurological function. Mechanistically, ranolazine decreased HIF-1α and GFAP expression while enhancing BDNF levels. Ranolazine increased mitochondrial complex enzyme activities (I, II, IV, and V) and enhanced the expression of the mitochondrial Tu translation elongation factor (TUFM), NRF1, and PGC-1α levels, indicating improved mitochondrial biogenesis and decreased mitochondrial oxidative stress markers such as 4-HNE and increased catalase and SOD. Further, ranolazine treatment reduced the levels of pro-inflammatory cytokines TNF-α and IL-6 while increasing the anti-inflammatory cytokine IL-10, suggesting its anti-inflammatory potential in mitigating the stroke-associated neuroinflammation. Moreover, ranolazine suppressed apoptosis by reducing the levels of apoptotic mediators such as cytochrome c, caspase-9, and caspase-3, and flow cytometry analysis revealed a significant decline in neuronal apoptosis, which further underscores its neuroprotective efficacy. Therefore, the novelty of this research lies in demonstrating that ranolazine exerts neuroprotective effects against ischemic brain injury by simultaneously modulating apoptotic pathways, restoring vital neurological factors (BDNF, TUFM, NRF-1, PGC-1α), improving mitochondrial function, reducing oxidative stress, and attenuating neuroinflammation, offering a novel multi-targeted therapeutic approach, meriting further clinical studies.
期刊介绍:
Metabolic Brain Disease serves as a forum for the publication of outstanding basic and clinical papers on all metabolic brain disease, including both human and animal studies. The journal publishes papers on the fundamental pathogenesis of these disorders and on related experimental and clinical techniques and methodologies. Metabolic Brain Disease is directed to physicians, neuroscientists, internists, psychiatrists, neurologists, pathologists, and others involved in the research and treatment of a broad range of metabolic brain disorders.